The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond

The article highlights AbbVie, Enbridge, and Realty Income as attractive high-yield dividend stocks, led by AbbVie's 3.3% forward yield and 53 consecutive years of dividend increases. Enbridge offers a 5.4% yield with 31 straight years of dividend hikes and roughly $50 billion of identified growth opportunities, while Realty Income yields 5% and has raised its monthly dividend for 31 consecutive years. The piece is largely a defensive income-stock recommendation rather than a market-moving event.

Analysis

The common thread here is not “high yield” per se, but cash-flow duration with different macro sensitivities. AbbVie is the cleanest value/growth mix, but the market is still underpricing how much of the next leg is driven by patent-cycle execution rather than headline yield; that makes it more of a 12-24 month rerating story than a short-term income trade. Enbridge and Realty Income are effectively duration assets in disguise: if rates stay elevated, their yields become more compelling as bond substitutes, but if the market starts pricing faster cuts, their relative appeal can compress even if fundamentals hold.

Second-order winner dynamics matter more than the article implies. Enbridge’s growth visibility is less about energy beta and more about locked-in infrastructure scarcity; that can lift contracted midstream peers and pressure smaller operators that lack scale, while the utility component acts as a volatility buffer in a way pure pipeline names do not. Realty Income’s Europe expansion is the underappreciated catalyst: it broadens the tenant pool and reduces single-country REIT risk, but it also imports FX and financing sensitivity, so the equity can de-rate if euro funding spreads widen.

The biggest contrarian point is that these names are being pitched as defensive income trades just as investors are crowding into the same factor basket. That usually makes the first drawdown less about earnings misses and more about Treasury volatility: a 50-75 bp backup in long yields can hit REITs and utility-like assets faster than fundamentals deteriorate. Conversely, if rate volatility falls, these stocks can rally even without upward estimate revisions because the market is currently paying for yield durability, not just growth.

Near term, the catalyst calendar is less important than macro path dependency. The cleanest reversal risk is a sharp move lower in yields or a broad risk-on rotation into duration-sensitive growth, which would make these income names look crowded rather than cheap. Over a 6-18 month horizon, AbbVie has the best asymmetry because execution can compound while the multiple remains undemanding; Enbridge is the steadiest carry; Realty Income offers the most optionality if Europe growth gets recognized before financing costs reprice.

Key Decisions for Investors

• Long ABBV for 6-12 months as a value-plus-growth rerating trade; target a modest multiple expansion driven by pipeline execution, with downside cushioned by cash-return credibility.
• Buy ENB on any pullback tied to crude weakness rather than rates; this is a 12-24 month toll-road cash flow trade, not a commodity call, with lower volatility than most energy exposure.
• Own O only if you want rate sensitivity plus income; consider waiting for a 10-year yield spike as the better entry, since the stock’s risk/reward improves when financing fears are already priced.
• Pair trade: long ABBV / short a basket of crowded high-yield defensives (e.g., O, utility proxies) if long-end yields keep backing up; ABBV has better earnings-driven upside and less pure duration exposure.
• If long O, hedge with Treasury futures or a small short in a REIT ETF for 3-6 months; the main risk is not tenant fundamentals but a sudden yield shock that compresses the dividend premium.